Rituxan

New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Flag link:
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Pharmaforum
Amgen
Allergan
biosimilar
Roche
Rituxan
Flag link:
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.
Fierce Pharma
Roche
Teva Pharmaceutical
Celltrion
Rituxan
biosimilars
MabThera
Truxima
Flag link:
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
Flag link:
Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders
Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders
Pharmaceutical Business Review
Roche
FDA
Rituxan
eosinophilic granulomatosis with polyangiitis
microscopic polyangiitis
Flag link:
Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study
Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study
Endpoints
Novartis
Amgen
Allergan
biosimilars
Roches
Rituxan
ABP 798
Flag link:
Roche clinches EU approval for MabThera in rare autoimmune indication — will it boost dwindling sales amid biosimiar competition?
Roche clinches EU approval for MabThera in rare autoimmune indication — will it boost dwindling sales amid biosimiar competition?
Endpoints
Roche
MabThera
Rituxan
Europe
biosimilars
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Celgene gets fast FDA review of Revlimid combo in lymphoma
Celgene gets fast FDA review of Revlimid combo in lymphoma
Pharmaforum
Celgene
Revlimid
FDA
Roche
Rituxan
priority review
Flag link:
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Flag link:
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Celgene
Revlimid
Roche
Rituxan
follicular lymphoma
Flag link:
FDA panel unanimously backs Celltrion's Rituxan biosimilar
FDA panel unanimously backs Celltrion's Rituxan biosimilar
Fierce Pharma
Celltrion
Teva Pharmaceutical
biosimilars
Rituxan
FDA
advisory panels
Flag link:
FDA reviewers endorse Celltrion's Rituxan biosimilar ahead of panel vote
FDA reviewers endorse Celltrion's Rituxan biosimilar ahead of panel vote
Fierce Pharma
Celltrion
Roche
biosimilars
Rituxan
FDA
advisory panels
Flag link:
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Endpoints
AbbVie
JNJ
FDA
Imbruvica
Rituxan
Roche
AstraZeneca
non-Hodgkin's lymphoma
Waldenström’s macroglobulinemia
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link:
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
Endpoints
AbbVie
Roche
Venclexta
Rituxan
CLL
chronic lymphocytic leukemia
Flag link:
FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris
FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris
CP Wire
Genentech
Rituxan
FDA
pemphigus vulgaris
Genentech/Roche
Flag link:
FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris
Genentech/Roche
Rituxan
pemphigus vulgaris
Flag link:
5 Best-Selling Orphan Drugs in the U.S.
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Flag link:
Celltrion resubmits Rituxan candidate in US, Herceptin version to follow
Celltrion resubmits Rituxan candidate in US, Herceptin version to follow
Biopharma Reporter
Celltrion
Rituxan
biosimilars
FDA
Herceptin
Roche
Biogen
CT-P10
Flag link:

Pages